For Doctors in a Hurry
- Researchers investigated whether glucagon-like peptide-1 receptor agonists can simultaneously treat psoriatic skin lesions and common cardiometabolic comorbidities.
- The National Psoriasis Foundation Medical Board synthesized evidence from small studies involving 7 to 48 patients over six months.
- Patients achieved Psoriasis Area and Severity Index reductions between 40% and 80% alongside decreased interleukin-6 and C-reactive protein levels.
- The authors concluded that these therapies target shared inflammatory pathways by reducing visceral adiposity and dermal gamma delta T-cell density.
- Clinicians may consider these agents as adjunctive therapy for patients with psoriasis and concurrent metabolic conditions pending larger trials.
Psoriasis is recognized as a systemic immune-mediated disorder frequently complicated by obesity, type 2 diabetes, and cardiovascular disease [1, 2]. These comorbidities are linked through shared immunopathogenic pathways, where chronic low-grade inflammation driven by pro-inflammatory cytokines such as tumor necrosis factor and interleukin-6 fuels both metabolic dysfunction and skin flares [1, 3]. While traditional management focuses on immune-modulating biologics, the high prevalence of excess adiposity in this population often impairs treatment response and worsens long-term outcomes [4, 5]. A meta-analysis of 11 randomized controlled trials involving 994 participants demonstrated that weight-loss interventions are associated with a significant reduction in disease severity, showing a mean difference in the Psoriasis Area and Severity Index (a clinical tool used to quantify the surface area and grade the redness and scaling of skin lesions) of -1.9 (95% CI -3.1 to -0.8, p < 0.001) [6]. Although clinical guidance on integrating metabolic regulators into dermatologic practice has remained sparse, recent data suggest that glucagon-like peptide-1 receptor agonists may improve skin lesions by inhibiting the expression of interleukin-17 and interleukin-23 [7, 8]. A new clinical primer from the US National Psoriasis Foundation Medical Board now provides a framework for using these incretin-based therapies (medications that mimic intestinal hormones to stimulate insulin release and suppress appetite) to address this complex intersection of metabolic and inflammatory pathology.
Clinical Efficacy and Quality of Life Outcomes
The clinical utility of glucagon-like peptide-1 (GLP-1) receptor agonists in dermatologic practice is primarily evidenced by their impact on the Psoriasis Area and Severity Index (PASI). The researchers found that these agents are associated with relative PASI reductions ranging from approximately 40% to 80%. These improvements in skin clearance are most pronounced in patients who present with comorbid obesity or type 2 diabetes. For the practicing physician, this suggests that the metabolic stabilization provided by these medications may directly influence cutaneous inflammation, potentially reducing the need for escalating doses of traditional immunosuppressants. Furthermore, the data indicate that these clinical improvements in skin morphology are accompanied by parallel gains in patient-reported quality of life, reflecting a broader benefit beyond objective physical markers.
While these results are clinically relevant, the current evidence base is characterized by several structural limitations that necessitate cautious interpretation. Most existing studies evaluating GLP-1 receptor agonists for psoriasis are small, with sample sizes ranging from only 7 to 48 patients. Additionally, the majority of these investigations are short term, with follow-up durations typically lasting 6 months or less. A significant proportion of the available data also stems from studies that lack a control group, which limits the ability to definitively isolate the drug effect from other variables. Despite these constraints, the consistent observation of substantial PASI reduction across multiple small cohorts provides a rationale for larger, more robust randomized clinical trials to confirm these initial findings.
Mechanisms of Immune and Adipose Modulation
The therapeutic effect of GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 agonists in psoriasis appears to stem from a dual mechanism involving both metabolic stabilization and direct immune modulation. The researchers found that these therapies target shared metabolic and inflammatory pathways that drive both psoriatic skin disease and its associated systemic comorbidities. Specifically, treatment with semaglutide and liraglutide is associated with significant reductions in systemic inflammatory markers, including C-reactive protein and interleukin-6, as well as improvements in lipid profiles. These findings suggest that the medications do not merely facilitate weight loss but actively dampen the systemic inflammatory state that characterizes psoriatic disease.
Beyond systemic markers, the study highlights how changes in body composition and skin-level immunology correlate with clinical improvement. Semaglutide and liraglutide are associated with reductions in visceral adiposity (fat stored around internal organs) and lipids. In small translational cohorts, researchers observed that improvements in the PASI score correlate directly with reductions in superficial adiposity (fat located in the subcutaneous layers). Furthermore, PASI improvement is linked to a decrease in dermal γδ T-cell density, a specific population of immune cells found in the skin that produces inflammatory cytokines like interleukin-17. By reducing the presence of these cells, GLP-1 receptor agonists may directly interrupt the local inflammatory cascade in the dermis. For dermatologists and primary care providers, this provides a cellular explanation for the observed reduction in skin lesion severity, reinforcing the concept that treating metabolic dysfunction can directly alter skin immunology.
Safety Profile and Polypharmacy Considerations
For clinicians managing complex psoriasis cases, the safety of polypharmacy is a primary concern when introducing newer metabolic agents. The National Psoriasis Foundation Medical Board reports that GLP-1 receptor agonists combine safely with standard systemic therapies, including methotrexate, cyclosporine, and various biologics. This compatibility is critical because many patients with severe psoriasis and metabolic comorbidities already require multi-drug regimens to achieve adequate disease control. The study indicates that adding these incretin-based therapies does not appear to compromise the efficacy or safety of established immunomodulatory treatments, allowing for a multi-pronged approach to systemic inflammation without compounding immunosuppression.
Regarding the tolerability profile, the researchers found that adverse effects are mainly transient gastrointestinal symptoms, such as nausea or diarrhea, which typically occur during the initial dose-escalation phase. These symptoms are generally self-limiting and manageable in a clinical setting without requiring the discontinuation of therapy. Furthermore, the study addresses concerns regarding more severe complications that have historically been monitored with this drug class; specifically, pancreatitis and gallbladder events associated with GLP-1 receptor agonists are rare. This safety data provides reassurance for physicians considering these agents as adjunctive therapy for patients who present with both cutaneous disease and significant metabolic burdens.
Practical Applications for the Clinician
The US National Psoriasis Foundation Medical Board primer provides an evidence-informed narrative synthesis and practical considerations for dermatologists and primary care physicians managing complex psoriatic disease. This guidance is particularly relevant because psoriasis is a chronic immune-mediated disease associated with a broad spectrum of cardiovascular, metabolic, musculoskeletal, psychiatric, hepatic, kidney, and pulmonary comorbidities. Because these systemic conditions often share inflammatory pathways with cutaneous disease, the researchers suggest that GLP-1 receptor agonists may serve a dual purpose in patient management. Currently, GLP-1 receptor agonists are approved by the US Food and Drug Administration for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (a severe form of liver inflammation caused by excess fat accumulation).
Given the high prevalence of these conditions among patients with skin disease, current evidence supports consideration of adjunctive use in selected patients with metabolic comorbidities. By utilizing agents that are already indicated for a patient's existing metabolic or renal conditions, clinicians may be able to improve skin clearance while simultaneously addressing underlying, life-limiting health risks. However, the authors maintain a cautious stance regarding broad implementation for skin clearance alone. They conclude that definitive conclusions regarding GLP-1 receptor agonists for psoriasis await larger randomized clinical trials, as current data are primarily derived from small, short-term observational studies that lack the statistical power of large-scale, controlled investigations.
References
1. Buonanno S, Gaggiano C, Terribili R, Cantarini L, Frediani B, Gentileschi S. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflammation Research. 2025. doi:10.1007/s00011-025-02140-2
2. Haran K, Johnson C, Smith P, et al. Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review. Psoriasis Targets and Therapy. 2024. doi:10.2147/ptt.s485061
3. Barrea L, Verde L, Annunziata G, et al. Medical Nutrition Therapy in Dermatological Diseases: A Joint Consensus Statement of the Italian Association of Dietetics and Clinical Nutrition (ADI), the Italian Society of Dermatology and Sexually Transmitted Diseases (SIDeMaST), the Italian Society of Nutraceuticals (SINut), Club Ketodiets and Nutraceuticals “KetoNut-SINut” and the Italian Society of Endocrinology (SIE), Club Nutrition, Hormones and Metabolism. Current Obesity Reports. 2025. doi:10.1007/s13679-025-00630-2
4. Siebert S, Sattar N, Ferguson LD. Weighing in on obesity and psoriatic arthritis – Time to move beyond association to robust randomised trials. Joint Bone Spine. 2025. doi:10.1016/j.jbspin.2025.105904
5. Rached NA, Gambichler T, Dietrich JW, et al. The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review. International Journal of Molecular Sciences. 2022. doi:10.3390/ijms232315250
6. Morrow S, Scragg J, Hawkins P, et al. P050 Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf085.078
7. Lin L, Xu X, Yunjie Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. Journal of Dermatological Treatment. 2020. doi:10.1080/09546634.2020.1826392
8. Śledziewska A, Sieradocha K, Cyrkler M, et al. Exploring the Potential of GLP-1 Receptor Agonists in Psoriasis Treatment: A Review Article. Archiv Euromedica. 2025. doi:10.35630/2025/15/3.316
